28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.
Latest Features
Plant Varieties
Applicants face tough scrutiny for claims around the laws of nature, but details of new processes, steps or guidance can help patents pass the courts’ two-step test, says Michael Taylor of Harness IP.
Biotechnology
It is critical that the emerging field of personalised medicine receives appropriate patent protection, explain Joel Coles and Theo Cooper of Powell Gilbert.
Unified Patent Court
Well-resourced NPEs looking to play the injunction card are eyeing up the court—companies with European operations should prepare, say Tom Oliver and Jessica Rosethorn of Powell Gilbert.
Biotechnology
Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs.
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.
Generics
While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
Biotechnology
Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper.
More News
19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.
14 March 2024 Japanese imaging and electronics firm has acquired non-exclusive licence from ERS Genomics | Technology will be used by Elixirgen Scientific, acquired by Ricoh in 2022.
12 March 2024 Pharma company’s new partnership is an “opportunity” to accelerate access and maximise the potential of AstraZenica’s asthma drug | Delhi-based pharma firm will provide valuable distribution channels.
12 March 2024 Danish drugmaker testing suspect products and assisting with legal cases | High demand and global shortages have driven surge in weight-loss drug fakes.
7 March 2024 WTO members failed to reach consensus on whether to expand patent waiver agreed in 2022 | Extended proposal would include tests and treatments for COVID-19.
7 March 2024 ‘Creative litigation strategist’ will expand firm’s capacity in complex technology areas | New hire joins from LTL Attorneys and spent much of career at Quinn Emanuel.
5 March 2024 Firm hires former Food and Drug Administration staffer from King & Spalding | Washington DC office gains nearly a decade of FDA experience.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox